Albireo Pharma, Inc. (NASDAQ: ALBO)

Engel Law PLLC is investigating whether fair value to Albireo shareholders will result from the proposed sale of Albireo Pharma, Inc. (NASDAQ: ALBO) to Ipsen for $42.00 per share plus one contingent value right (CVR) of $10.00 per share.

The Firm’s investigation concerns:

(i) whether Albireo’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the $42.00 per share plus a contingent value right (CVR) of $10.00 per share merger consideration adequately compensates Albireo’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Albireo Pharma, Inc.

Full Name or Entity

If Representing an Entity, Position at Entity

Address

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Phone

Date You Acquired Share(s)

Date Shares Were Acquired

Cost Per Share

Note

Consent(Required)

By clicking on the SUBMIT button below, I acknowledge that I have read the Retainer Agreement and agree to retain Engel Law PLLC to file an action or issue a shareholder demand against the Company in connection with this matter. Engel Law PLLC will prosecute this action on a contingent fee basis and will advance all costs and expenses.

Date of Signing(Required)

Albireo Pharma, Inc. (NASDAQ: ALBO)

Join this Action

Albireo Pharma, Inc.

ENGEL LAW PLLC